ArticleBioMed research international2026
Development, Characterization, and Evaluation of Topical Antibacterial Formulations From Achyranthes aspera.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development, Characterization, and Evaluation of Topical Antibacterial Formulations From Achyranthes aspera.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Skin diseases are a significant global health issue, particularly in developing nations. However, the efficiency of topical antibacterial treatments is diminishing due to the development of resistance. This study is aimed at developing and evaluating topical antibacterial formulations from Achyranthes aspera, a plant traditionally used for wound healing. The Kirby-Bauer method was employed to examine the antibacterial activity of hydroalcoholic extracts obtained from fresh and dried leaves of A. aspera. The fraction, which demonstrated the highest antibacterial activity, underwent further testing to determine its minimum inhibitory concentration (MIC) and was employed to formulate eight different topical formulations. These formulations were subsequently evaluated for their antibacterial effectiveness, sensory properties, pH, viscosity, spreadability, and acute dermal toxicity and underwent FTIR compatibility analysis and 3-month accelerated stability studies (40°C/75% RH). The results indicated that the 70% hydroalcoholic extracts of A. aspera were effective against common skin bacteria, particularly Staphylococcus aureus. Among the fractions tested, the chloroform fraction exhibited the largest zones of inhibition (16.50 ± 0.76 mm for S. aureus and 15.33 ± 0.33 mm for Pseudomonas aeruginosa) and an MIC of 3.125 mg/mL for both bacteria. Among the eight formulations, the basic cream demonstrated the highest antibacterial performance with a ZI of 19 ± 0.577, followed by the emulsifying ointments. FTIR analysis confirmed the absence of chemical interactions between the active fraction and formulation excipients. All formulations displayed favorable pH levels, good spreadability, homogeneity, and stability and did not cause irritation when applied to mice at a dosage of 2000 mg/kg. The accelerated stability study confirmed that the basic cream and emulsifying ointment maintained their physicochemical properties and antibacterial efficacy over 3 months. The findings suggest that A. aspera chloroform fractions are promising for developing effective topical treatments for S. aureus-related skin infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.